BOAN BIOTECH (06955.HK): Denosumab 60mg Licensing Deal in Japan

NewTimeSpace News: On 30 October 2026, Shandong Boan Biotechnology Co., Ltd. (stock code: 06955) voluntarily announced that it has entered into a collaboration agreement with a partner over the Japanese market rights to its denosumab injection 60mg (BA6101).

The announcement stated that the partner will obtain exclusive commercialisation rights to the product in Japan, including promotion, sales and registration filing, and will be fully responsible for its development and market access in Japan. The company will receive upfront, milestone and royalty payments. Denosumab is a RANK ligand (RANKL) inhibitor, and BA6101 is a biosimilar of Prolia® (Pralia® in Japan), which has been approved in Japan for the treatment of osteoporosis and the inhibition of bone erosion progression associated with rheumatoid arthritis.

According to the announcement, Japan has about 15.9 million osteoporosis patients aged 40 and above and about 825,000 rheumatoid arthritis patients, and Pralia® recorded Japanese sales of JPY 45.8 billion in 2025, up 8.3% year on year. BA6101 was independently developed under the company's global R&D strategy and, as the first domestic denosumab, was approved in China in 2022. It has also been approved in Bolivia and is under marketing authorisation review in the UK and the US.